News

Abbott Laboratories CEO calls post-earnings stock decline ‘a little bit of an overreaction'
Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...
Notable healthcare headlines for the week: Trump’s tariff threats, J&J, Abbott Laboratories and Sarepta in focus
Just a day after the S&P 500 and Nasdaq climbed into record territory, U.S. stocks end mixed, with American Express (AXP) and 3M (MMM) dragging the Dow, and more tariff drama muting markets.
Crain's Chicago Business3d
Abbott falls on outlook cut, sees $200 million tariff impact
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...
Abbott upgraded after post-earnings selloff, hardware drag seen temporary
Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...
Abbott Laboratories falls after setting Q3 outlook below consensus
Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...
Should You Buy Abbott Stock At $135?
Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...
Explore more
Abbott Laboratories stock outperforms competitors on strong trading day
Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.
Abbott Earnings Beat Forecasts. Why the Stock Is Having Its Worst Day Since 2021.
Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...
Abbott upgraded to Buy at Jefferies despite underwhelming outlook
Abbott Laboratories ( NYSE: ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as ...